Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028
Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028.
Related stories
Coherent Reports Fiscal Q1 Revenue of $2.37 Billion, Raises Long-Term Margin Target
Coherent reported revenue up 50% year over year, with GAAP and non-GAAP gross margins of 39.1% and 40.6%. It guided Q2 revenue to $2.55 billion-$2.75 billion and adjusted EPS to $2
M impact | EQUITY | Nov 04, 2026, 11:02 PM UTC
US session market picture: S&P 500 +1.81%, Nasdaq 100 +1.2%; EUR/USD +0.38%, WTI -8.38%, WBD leads volume
US session market picture. US index futures: S and P futures is up 1.81 percent, Nasdaq futures is up 1.2 percent, Dow futures is up 3.27 percent and Russell futures is up 1.64 per
M impact | EQUITY | Nov 04, 2026, 11:01 PM UTC
ASX Futures Rise 2.0% Ahead of Open as Oil Prices Sink
ASX futures are up 2.0% ahead of the open, suggesting the S&P/ASX 200 may follow gains in U.S. shares. The report links weaker oil prices to hopes a Democratic sweep in the U.S. mi
M impact | EQUITY | Nov 04, 2026, 10:59 PM UTC
Terreno Realty Q3 Revenue Beats on New and Renewed Leases
M impact | EQUITY | Nov 04, 2026, 10:57 PM UTC
Coca-Cola Consolidated reports Q3 earnings
Coca-Cola Consolidated reported its Q3 results.
M impact | EQUITY | Nov 04, 2026, 10:56 PM UTC
ARM Holdings Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 04, 2026, 10:55 PM UTC